Insomnia and triglycerides in schizophrenia
- ,
- Department of Psychiatry and Health Behavior,
- ,
- ,
- Physiology & Graduate Studies,
- Departments of Medicine and Rehabilitation Medicine
Scholary Output:
Contribution to journal
Article
Peer-reviewSustainable Development Goals
SDG 3 Good Health and Well
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 42-43 (2 pages)Journal (Volume, Issue Number)
Schizophrenia Research (Volume 239)Publication milestones
- E-pub ahead of print - 11/25/2021
- Published - 01/2022
Publication status
Published - 01/2022
ISSN
0920-9964Publication IDs
- PubMed: 34839072
- ORCID: /0000-0001-5035-7858/work/104221248
- Scopus: 85119936577
- PubMed: 34839072
Publication metrics
Metrics
Fractional count
4
Fractional count
1
Fractional count
4
Fractional count
1
PlumX, opens in new tab
Captures
5
Citation count
6
Funding Details
Dr. Miller has nothing to disclose for the work under consideration. In the past 12 months, Dr. Miller received research support from Augusta University, the National Institute of Mental Health, and the Stanley Medical Research Institute; participated in Advisory Boards for Boehringer Ingelheim; and Honoraria from Psychiatric Times.Dr. McCall has nothing to disclose for the work under consideration. In the past 12 months, Dr. McCall has received honoraria from Wolters Kluwer Publishing, CME Outfitters, and Anthem Inc., and research support from Merck and MECTA Corp, and is a scientific advisor for Sage Therapeutics, Janssen, and Jazz.Dr. Harris has nothing to disclose for the work under consideration. In the past 12 months, Dr. Harris has received research support from the National Institutes of Health, Cystic Fibrosis Foundation Therapeutics, and Vertex Pharmaceuticals.
Dr. Harris has nothing to disclose for the work under consideration. In the past 12 months, Dr. Harris has received research support from the National Institutes of Health , Cystic Fibrosis Foundation Therapeutics , and Vertex Pharmaceuticals .